APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Influenza Treatment Market Analysis and Forecast 2026-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchInfluenza Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Influenza Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Treatment Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Influenza Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Influenza Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Influenza Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Influenza Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Influenza Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Influenza Treatment include Sanofi, Novartis AG, GSK plc., Daiichi Sankyo, AstraZeneca, Viatris Inc. (Mylan), Teva Pharmaceutical Industries Ltd., Roche Holding and NATCO Pharma Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Influenza Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Influenza Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Influenza Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenza Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Influenza Treatment revenue, projected growth trends, production technology, application and end-user industry.

Influenza Treatment Segment by Company

Sanofi

Novartis AG

GSK plc.

Daiichi Sankyo

AstraZeneca

Viatris Inc. (Mylan)

Teva Pharmaceutical Industries Ltd.

Roche Holding

NATCO Pharma Limited

Gilead Sciences

BioCryst Pharmaceuticals

Influenza Treatment Segment by Type

Zanamivir

Peramivir

Oseltamivir Phosphate

Baloxavir Marboxil

Others

Influenza Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Influenza Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Influenza Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Influenza Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenza Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Zanamivir Major Player Table 3. Peramivir Major Player Table 4. Oseltamivir Phosphate Major Player Table 5. Baloxavir Marboxil Major Player Table 6. Others Major Player Table 7. Global Influenza Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Pharmacies Major Player Table 9. Online Pharmacies Major Player Table 10. Retail Pharmacies Major Player Table 11. Influenza Treatment Industry Trends Table 12. Influenza Treatment Industry Drivers Table 13. Influenza Treatment Industry Opportunities and Challenges Table 14. Influenza Treatment Industry Restraints Table 15. Global Influenza Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Influenza Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Influenza Treatment Market Share by Region (2021-2026) Table 18. Global Influenza Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Influenza Treatment Market Share by Region (2027-2032) Table 20. Global Influenza Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Influenza Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Influenza Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Influenza Treatment Key Players Headquarters & Area Served Table 24. Global Influenza Treatment Players, Product Type & Application Table 25. Global Influenza Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Influenza Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Influenza Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Influenza Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Influenza Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Influenza Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Influenza Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Influenza Treatment Revenue Market Share by Application (2027-2032) Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi Influenza Treatment Product Portfolio Table 42. Sanofi Recent Development Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Novartis AG Influenza Treatment Product Portfolio Table 47. Novartis AG Recent Development Table 48. GSK plc. Company Information Table 49. GSK plc. Business Overview Table 50. GSK plc. Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GSK plc. Influenza Treatment Product Portfolio Table 52. GSK plc. Recent Development Table 53. Daiichi Sankyo Company Information Table 54. Daiichi Sankyo Business Overview Table 55. Daiichi Sankyo Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Daiichi Sankyo Influenza Treatment Product Portfolio Table 57. Daiichi Sankyo Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. AstraZeneca Influenza Treatment Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Viatris Inc. (Mylan) Company Information Table 64. Viatris Inc. (Mylan) Business Overview Table 65. Viatris Inc. (Mylan) Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Viatris Inc. (Mylan) Influenza Treatment Product Portfolio Table 67. Viatris Inc. (Mylan) Recent Development Table 68. Teva Pharmaceutical Industries Ltd. Company Information Table 69. Teva Pharmaceutical Industries Ltd. Business Overview Table 70. Teva Pharmaceutical Industries Ltd. Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Teva Pharmaceutical Industries Ltd. Influenza Treatment Product Portfolio Table 72. Teva Pharmaceutical Industries Ltd. Recent Development Table 73. Roche Holding Company Information Table 74. Roche Holding Business Overview Table 75. Roche Holding Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Roche Holding Influenza Treatment Product Portfolio Table 77. Roche Holding Recent Development Table 78. NATCO Pharma Limited Company Information Table 79. NATCO Pharma Limited Business Overview Table 80. NATCO Pharma Limited Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. NATCO Pharma Limited Influenza Treatment Product Portfolio Table 82. NATCO Pharma Limited Recent Development Table 83. Gilead Sciences Company Information Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences Influenza Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Gilead Sciences Influenza Treatment Product Portfolio Table 87. Gilead Sciences Recent Development Table 88. BioCryst Pharmaceuticals Company Information Table 89. BioCryst Pharmaceuticals Business Overview Table 90. BioCryst Pharmaceuticals Influenza Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. BioCryst Pharmaceuticals Influenza Treatment Product Portfolio Table 92. BioCryst Pharmaceuticals Recent Development Table 93. North America Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Influenza Treatment Revenue by Country (2021-2026) & (US$ Million) Table 99. North America Influenza Treatment Revenue by Country (US$ Million) & (2027-2032) Table 100. Europe Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. Europe Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. Europe Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Europe Influenza Treatment Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Influenza Treatment Revenue by Country (US$ Million) & (2027-2032) Table 107. China Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 108. China Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 109. China Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 110. China Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 112. Asia Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 113. Asia Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 114. Asia Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Influenza Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Asia Influenza Treatment Revenue by Region (US$ Million) & (2021-2026) Table 117. Asia Influenza Treatment Revenue by Region (US$ Million) & (2027-2032) Table 118. SAMEA Influenza Treatment Revenue by Type (2021-2026) & (US$ Million) Table 119. SAMEA Influenza Treatment Revenue by Type (2027-2032) & (US$ Million) Table 120. SAMEA Influenza Treatment Revenue by Application (2021-2026) & (US$ Million) Table 121. SAMEA Influenza Treatment Revenue by Application (2027-2032) & (US$ Million) Table 122. SAMEA Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. SAMEA Influenza Treatment Revenue by Country (2021-2026) & (US$ Million) Table 124. SAMEA Influenza Treatment Revenue by Country (US$ Million) & (2027-2032) Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Influenza Treatment Image Figure 2. Global Influenza Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Zanamivir Image Figure 5. Peramivir Image Figure 6. Oseltamivir Phosphate Image Figure 7. Baloxavir Marboxil Image Figure 8. Others Image Figure 9. Global Influenza Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Influenza Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Retail Pharmacies Image Figure 14. Global Influenza Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Influenza Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Influenza Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Influenza Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Influenza Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Influenza Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Influenza Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Influenza Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Influenza Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Influenza Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Influenza Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Influenza Treatment Revenue Share by Type (2021-2032) Figure 27. North America Influenza Treatment Revenue Share by Application (2021-2032) Figure 28. North America Influenza Treatment Revenue Share by Country (2021-2032) Figure 29. United States Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Influenza Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Influenza Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Influenza Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Influenza Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Influenza Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Influenza Treatment Revenue Share by Type (2021-2032) Figure 46. China Influenza Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Influenza Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Influenza Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Influenza Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Influenza Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Influenza Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Influenza Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Influenza Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Influenza Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Influenza Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Zanamivir
  • Peramivir
  • Oseltamivir Phosphate
  • Baloxavir Marboxil
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sanofi
  • Novartis AG
  • GSK plc.
  • Daiichi Sankyo
  • AstraZeneca
  • Viatris Inc. (Mylan)
  • Teva Pharmaceutical Industries Ltd.
  • Roche Holding
  • NATCO Pharma Limited
  • Gilead Sciences
  • BioCryst Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenza Treatment Market by Type
  3. 1.2.1 Global Influenza Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Zanamivir
  5. 1.2.3 Peramivir
  6. 1.2.4 Oseltamivir Phosphate
  7. 1.2.5 Baloxavir Marboxil
  8. 1.2.6 Others
  9. 1.3 Influenza Treatment Market by Application
  10. 1.3.1 Global Influenza Treatment Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Retail Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Influenza Treatment Market Dynamics
  1. 2.1 Influenza Treatment Industry Trends
  2. 2.2 Influenza Treatment Industry Drivers
  3. 2.3 Influenza Treatment Industry Opportunities and Challenges
  4. 2.4 Influenza Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Influenza Treatment Market Perspective (2021-2032)
  2. 3.2 Global Influenza Treatment Growth Trends by Region
  3. 3.2.1 Global Influenza Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenza Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Influenza Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Influenza Treatment Revenue by Players
  2. 4.1.1 Global Influenza Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Influenza Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Influenza Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenza Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Influenza Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Influenza Treatment Players, Product Type & Application
  8. 4.5 Global Influenza Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Influenza Treatment Market CR5 and HHI
  11. 4.6.3 2025 Influenza Treatment Tier 1, Tier 2, and Tier 3
5 Influenza Treatment Market Size by Type
  1. 5.1 Global Influenza Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Influenza Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Influenza Treatment Revenue Market Share by Type (2021-2032)
6 Influenza Treatment Market Size by Application
  1. 6.1 Global Influenza Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Influenza Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Influenza Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Influenza Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Influenza Treatment Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Influenza Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Influenza Treatment Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 GSK plc.
  14. 7.3.1 GSK plc. Company Information
  15. 7.3.2 GSK plc. Business Overview
  16. 7.3.3 GSK plc. Influenza Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GSK plc. Influenza Treatment Product Portfolio
  18. 7.3.5 GSK plc. Recent Developments
  19. 7.4 Daiichi Sankyo
  20. 7.4.1 Daiichi Sankyo Company Information
  21. 7.4.2 Daiichi Sankyo Business Overview
  22. 7.4.3 Daiichi Sankyo Influenza Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Daiichi Sankyo Influenza Treatment Product Portfolio
  24. 7.4.5 Daiichi Sankyo Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Influenza Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Influenza Treatment Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Viatris Inc. (Mylan)
  32. 7.6.1 Viatris Inc. (Mylan) Company Information
  33. 7.6.2 Viatris Inc. (Mylan) Business Overview
  34. 7.6.3 Viatris Inc. (Mylan) Influenza Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Viatris Inc. (Mylan) Influenza Treatment Product Portfolio
  36. 7.6.5 Viatris Inc. (Mylan) Recent Developments
  37. 7.7 Teva Pharmaceutical Industries Ltd.
  38. 7.7.1 Teva Pharmaceutical Industries Ltd. Company Information
  39. 7.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
  40. 7.7.3 Teva Pharmaceutical Industries Ltd. Influenza Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Teva Pharmaceutical Industries Ltd. Influenza Treatment Product Portfolio
  42. 7.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  43. 7.8 Roche Holding
  44. 7.8.1 Roche Holding Company Information
  45. 7.8.2 Roche Holding Business Overview
  46. 7.8.3 Roche Holding Influenza Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Holding Influenza Treatment Product Portfolio
  48. 7.8.5 Roche Holding Recent Developments
  49. 7.9 NATCO Pharma Limited
  50. 7.9.1 NATCO Pharma Limited Company Information
  51. 7.9.2 NATCO Pharma Limited Business Overview
  52. 7.9.3 NATCO Pharma Limited Influenza Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 NATCO Pharma Limited Influenza Treatment Product Portfolio
  54. 7.9.5 NATCO Pharma Limited Recent Developments
  55. 7.10 Gilead Sciences
  56. 7.10.1 Gilead Sciences Company Information
  57. 7.10.2 Gilead Sciences Business Overview
  58. 7.10.3 Gilead Sciences Influenza Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Gilead Sciences Influenza Treatment Product Portfolio
  60. 7.10.5 Gilead Sciences Recent Developments
  61. 7.11 BioCryst Pharmaceuticals
  62. 7.11.1 BioCryst Pharmaceuticals Company Information
  63. 7.11.2 BioCryst Pharmaceuticals Business Overview
  64. 7.11.3 BioCryst Pharmaceuticals Influenza Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 BioCryst Pharmaceuticals Influenza Treatment Product Portfolio
  66. 7.11.5 BioCryst Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Influenza Treatment Revenue (2021-2032)
  2. 8.2 North America Influenza Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Influenza Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Influenza Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Influenza Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Influenza Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Influenza Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Influenza Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Influenza Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Influenza Treatment Revenue by Country
  11. 8.6.1 North America Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Influenza Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Influenza Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Influenza Treatment Revenue (2021-2032)
  2. 9.2 Europe Influenza Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Influenza Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Influenza Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Influenza Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Influenza Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Influenza Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Influenza Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Influenza Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Influenza Treatment Revenue by Country
  11. 9.6.1 Europe Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Influenza Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Influenza Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Influenza Treatment Revenue (2021-2032)
  2. 10.2 China Influenza Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Influenza Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Influenza Treatment Revenue by Type (2027-2032)
  5. 10.3 China Influenza Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Influenza Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Influenza Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Influenza Treatment Revenue by Application (2027-2032)
  9. 10.5 China Influenza Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenza Treatment Revenue (2021-2032)
  2. 11.2 Asia Influenza Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Influenza Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Influenza Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Influenza Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Influenza Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Influenza Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Influenza Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Influenza Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Influenza Treatment Revenue by Country
  11. 11.6.1 Asia Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Influenza Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Influenza Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenza Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Influenza Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Influenza Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Influenza Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Influenza Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Influenza Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Influenza Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Influenza Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Influenza Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Influenza Treatment Revenue by Country
  11. 12.6.1 SAMEA Influenza Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Influenza Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Influenza Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst